CIK 0001326190 · Non-accelerated filer<br>Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 202726770
- Phone
- 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Howarth Alex G. Director | Grant or award · Stock Options (option to buy) | +160,000 | 160,000 | ||
| 2026-11-02 | Greenleaf Peter Director | Grant or award · Stock Options (option to buy) | +160,000 | 160,000 | ||
| 2026-10-01 | Arbet-Engels Christophe Chief Medical Officer | Option exercise | +37,500 | 37,500 | ||
| 2026-10-01 | Arbet-Engels Christophe Chief Medical Officer | Shares withheld for taxes | −12,679 | $2.76 | $35K | 24,821 |
| 2026-10-01 | Arbet-Engels Christophe Chief Medical Officer | Option exercise · Restricted Stock Units | −37,500 | 112,500 | ||
| 2026-10-01 | WEAVER GREGORY L Chief Financial Officer | Option exercise | +14,475 | 54,306 | ||
| 2026-10-01 | WEAVER GREGORY L Chief Financial Officer | Shares withheld for taxes | −4,379 | $2.76 | $12K | 49,927 |
| 2026-10-01 | WEAVER GREGORY L Chief Financial Officer | Option exercise · Restricted Stock Units | −14,475 | 43,425 | ||
| 2026-10-01 | MENZIUSO RICHARD THOMAS Principal Accounting Officer | Grant or award · Stock Options (option to buy) | +84,546 | 84,546 | ||
| 2026-10-01 | MENZIUSO RICHARD THOMAS Principal Accounting Officer | Grant or award · Restricted Stock Units | +36,234 | 36,234 | ||
| 2026-09-16 | Richardson Linda M Chief Commercial Officer | Option exercise | +24,000 | 24,000 | ||
| 2026-09-16 | Richardson Linda M Chief Commercial Officer | Shares withheld for taxes | −6,826 | $3.24 | $22K | 17,174 |
| 2026-09-16 | Richardson Linda M Chief Commercial Officer | Option exercise · Restricted Stock Units | −24,000 | 72,000 | ||
| 2026-08-13 | Durso Jerome Benedict President and CEO | Purchase | +15,000 | $2.95 | $44K | 62,500 |
| 2026-07-31 | Roberts M Scot Chief Scientific Officer | Grant or award | +875 | $2.41 | $2K | 113,699 |
| 2026-07-31 | WEAVER GREGORY L Chief Financial Officer | Grant or award | +1,753 | $2.41 | $4K | 39,831 |
| 2026-05-01 | Lawver Teri L Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-05-01 | Pisano Wayne Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-05-01 | Schafer Klaus Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-05-01 | Hodges Philip Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 |
Page 1 of 21 · 403 trades